Información de CureVac NV, dividendo de CureVac NV, actividades de los accionistas y más

Más Datos de CureVac NV Compañía

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Información de CureVac NV



Símbolo de cotizaciónCVAC

Nombre de la empresaCureVac NV

Fecha de salida a bolsaAug 14, 2020

Director ejecutivoDr. Alexander Zehnder, M.D.

Número de empleados825

Tipo de seguridadOrdinary Share

Fin del año fiscalAug 14

DirecciónFriedrich-Miescher-Str. 15

CiudadTUEBINGEN

Bolsa de valoresNASDAQ Global Market Consolidated

PaísGermany

Código postal72076

Teléfono49707198830

Sitio Webhttps://www.curevac.com/

Símbolo de cotizaciónCVAC

Fecha de salida a bolsaAug 14, 2020

Director ejecutivoDr. Alexander Zehnder, M.D.

Ejecutivos de CureVac NV



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Baron Jean Stephenne

Independent Chairman of Supervisory Board

40.49K

+141.65%

Dr. Mathias Hothum, Ph.D.

Member of the Supervisory Board

29.31K

+170.24%

Mr. Craig A. Tooman

Independent Member of the Supervisory Board

27.79K

+187.92%

Mr. Michael Brosnan

Independent Member of the Supervisory Board

19.75K

+371.79%

Mr. Axel-Sven Malkomes

Chief Financial Officer

--

Dr. Klaus Schollmeier, Ph.D.

Independent Member of the Supervisory Board

--

Dr. Malte Greune, Ph.D.

Chief Operating Officer, Member of the Management Board

--

Dr. Debra Barker, M.D.

Member of the Supervisory Board

--

Dr. Alexander Zehnder, M.D.

Chief Executive Officer, Member of the Management Board

--

Dr. Myriam Mendila, M.D.

Chief Scientific Officer, Member of the Management Board

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Baron Jean Stephenne

Independent Chairman of Supervisory Board

40.49K

+141.65%

Dr. Mathias Hothum, Ph.D.

Member of the Supervisory Board

29.31K

+170.24%

Mr. Craig A. Tooman

Independent Member of the Supervisory Board

27.79K

+187.92%

Mr. Michael Brosnan

Independent Member of the Supervisory Board

19.75K

+371.79%

Mr. Axel-Sven Malkomes

Chief Financial Officer

--

Dr. Klaus Schollmeier, Ph.D.

Independent Member of the Supervisory Board

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Sin datos

Por regiónUSD

Nombre

Ganancia

Proporción

Switzerland

1.06M

85.06%

Belgium (Country)

186.00K

14.94%

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: lun., 10 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

DH Capital GmbH & Co. KG

31.17%

KfW

13.27%

Glaxo Group, Ltd.

7.37%

DH-LT-Investments GmbH

3.89%

Zweite DH Verwaltungs GmbH

1.51%

Otro

42.80%

Accionistas

Proporción

DH Capital GmbH & Co. KG

31.17%

KfW

13.27%

Glaxo Group, Ltd.

7.37%

DH-LT-Investments GmbH

3.89%

Zweite DH Verwaltungs GmbH

1.51%

Otro

42.80%

Tipos de accionistas

Accionistas

Proporción

Corporation

36.61%

Government Agency

13.27%

Holding Company

7.37%

Hedge Fund

2.12%

Investment Advisor/Hedge Fund

1.85%

Investment Advisor

1.18%

Foundation

0.70%

Research Firm

0.69%

Bank and Trust

0.25%

Otro

35.96%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

245

15.20M

6.75%

-13.07M

2025Q2

250

140.06M

62.20%

-14.31M

2025Q1

256

140.77M

62.52%

-15.67M

2024Q4

257

142.22M

63.40%

-15.15M

2024Q3

264

144.04M

64.21%

-15.50M

2024Q2

284

147.06M

65.56%

-13.88M

2024Q1

303

150.44M

67.06%

-10.89M

2023Q4

317

154.94M

69.64%

-16.33M

2023Q3

339

166.99M

75.03%

-5.02M

2023Q2

359

168.77M

75.83%

-4.22M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

DH Capital GmbH & Co. KG

70.18M

31.17%

--

Jun 12, 2025

KfW

29.87M

13.27%

--

Aug 01, 2025

Glaxo Group, Ltd.

16.59M

7.37%

--

Aug 07, 2025

DH-LT-Investments GmbH

8.75M

3.89%

--

Jun 12, 2025

Zweite DH Verwaltungs GmbH

3.40M

1.51%

--

Jun 12, 2025

Alpine Associates Management Inc.

1.97M

0.88%

+1.97M

--

Jun 30, 2025

Bill & Melinda Gates Foundation

1.57M

0.7%

-28.77K

-1.80%

Sep 30, 2024

Qube Research & Technologies Ltd

1.18M

0.53%

+1.18M

--

Jun 30, 2025

Water Island Capital, LLC

957.03K

0.42%

+957.03K

--

Jun 30, 2025

Glazer Capital, LLC

594.85K

0.26%

+594.85K

--

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

AltShares Merger Arbitrage ETF

1.3%

Virtus LifeSci Biotech Clinical Trials ETF

0.69%

Global X Genomics & Biotechnology ETF

0.59%

NYLI Merger Arbitrage ETF

0.57%

WisdomTree BioRevolution Fund

0.5%

ProShares Ultra Nasdaq Biotechnology

0.13%

Invesco Nasdaq Biotechnology ETF

0.12%

SPDR S&P International Small Cap ETF

0.05%

iShares Biotechnology ETF

0.05%

iShares MSCI Europe Small-Cap ETF

0.04%

AltShares Merger Arbitrage ETF

Proporción1.3%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.69%

Global X Genomics & Biotechnology ETF

Proporción0.59%

NYLI Merger Arbitrage ETF

Proporción0.57%

WisdomTree BioRevolution Fund

Proporción0.5%

ProShares Ultra Nasdaq Biotechnology

Proporción0.13%

Invesco Nasdaq Biotechnology ETF

Proporción0.12%

SPDR S&P International Small Cap ETF

Proporción0.05%

iShares Biotechnology ETF

Proporción0.05%

iShares MSCI Europe Small-Cap ETF

Proporción0.04%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos